.jpg "Celldex (NASDAQ: CLDX)")
Jefferies analyst Biren Amin reiterated a Hold rating on Celldex (NASDAQ: CLDX) today and set a price target of $0.50. The company’s shares opened today at $0.44, close to its 52-week low of $0.41.
According to TipRanks.com, Amin is a 5-star analyst with an average return of 16.2% and a 54.5% success rate. Amin covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Armo Biosciences Inc, and Heron Therapeutics.
Currently, the analyst consensus on Celldex is a Moderate Buy with an average price target of $1.33, a 201.2% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Celldex’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.41 million. In comparison, last year the company had a GAAP net loss of $28.57 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company’s drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.
